Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
An analysis of data on more than 10,000 women with inflammatory breast cancer looked at the use of trimodality treatment, in which three treatment types (surgery, chemotherapy and radiation therapy) are used. The study found that women who had this type of therapy lived longer than women who did not.
Researchers say if a woman is obese before, shortly after or more than a year after being diagnosed with breast cancer, her risk of dying from cancer or from any cause is higher than that of a woman with breast cancer who is a healthy weight.
Researchers found only about a third of women are exercising enough after being diagnosed with breast cancer. They say women, especially African-Americans, should be given more information from their healthcare teams about the benefits of exercise.
A recent study found that though complementary therapy use is widespread, many women don’t understand the impact some therapies may have on their breast cancer treatment or general health. Complementary therapies are non-medical approaches to care used along with medical treatment, such as acupuncture, tai chi and meditation.
The American Society of Clinical Oncology, ASCO, released a new treatment guideline for HER2-negative breast cancer that has spread from the breast to nearby areas or distant parts of the body.
Researchers suggest healthcare providers take note of the connection between distress caused by lymphedema and poor mental and physical health and use this information to help women with breast cancer.
Researchers suggest more studies be done on carboplatin to find out if it could have long-term benefits and to see what types of people with triple-negative breast cancer it helps most.
Final results of the phase III TH3RESA trial confirm that the medicine T-DM1 extends progression-free survival, PFS, in people who have HER2-positive metastatic breast cancer that no longer responds well to first-line treatments, such as trastuzumab. PFS is the time from the start of treatment until the disease grows or spreads.
Early results of this study were presented at the European Cancer Congress, in Amsterdam, in the fall of 2013.
An article published in JAMA Surgery suggests that even while some state laws are mandating changes in the way doctors discuss the safety of breast implants and the pros and cons of having immediate or delayed reconstruction, gaps in education still remain.
Final results from the CLEOPATRA trial were presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid at the end of September. They were also later published in the New England Journal of Medicine, in February 2015. The results show the combination of trastuzumab and pertuzumab, along with chemotherapy, lengthened the lives of women with HER2-positive metastatic breast cancer by a median 15.7 months. The increase is being called unprecedented.